Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260176 | 1.00 | TDP1 (0.43) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL4473312 | 1.00 | TDP1 (0.43) | TDP1MAOAMAOBMEN1GAA | |
| Hydrochloric Acid SCHEMBL22121480 | 0.98 | TDP1 (0.42) | TDP1MAOAMAOBMEN1GAA | |
| Hydrochloric Acid SCHEMBL21616394 | 0.98 | TDP1 (0.42) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18262010 | 0.90 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18262007 | 0.90 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18487257 | 0.90 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL17302431 | 0.86 | TDP1 (0.41) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL23992116 | 0.84 | TDP1 (0.30) | TDP1 | |
| SCHEMBL661593 | 0.83 | TDP1 (0.49) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637480-B2 | Heterocyclic compounds as sting modulators | BEONE MEDICINES I GMBH (CH) | 2026-05-26 | — | — | US | disclosed |
| CN-122036541-A | Amino acid-based ionizable lipid compound, and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2026-05-15 | — | — | CN | disclosed |
| EP-4007758-B1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | MERSANA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4673445-A1 | STING AGONISTS CONTAINING BENZYLIC ALCOHOL AND BENZYLIC AMINE FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673439-A1 | STING AGONISTS CONTAINING HYDRAZIDE, HYDRAZINE, AND HYDROXAMIC ACID FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025233676-A1 | COMPOSITIONS AND METHODS RELATED TO A COMBINATION THERAPY OF STING AGONISTS AND IMMUNE CHECKPOINT INHIBITORS | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025233682-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS AND USES THEREOF | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025233679-A1 | COMPOSITIONS AND METHODS RELATED TO A COMBINATION THERAPY OF STING AGONISTS AND ANTIBODY DRUG CONJUGATES | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | disclosed |
| US-20250313557-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVE COMPOUNDS AS TLR7/8 MODULATORS | LIGACHEM BIOSCIENCES INC. (KR) | 2025-10-09 | — | — | US | disclosed |
| EP-4620959-A1 | CYCLIC COMPOUNDS USED AS MULTI-TARGET KINASE INHIBITORS AND PREPARATION METHOD THEREFOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2025-09-24 | — | — | EP | disclosed |
| WO-2016196956-A1 | CELL-PERMEABLE, CELL-COMPATIBLE, AND CLEAVABLE LINKERS FOR COVALENT TETHERING OF FUNCTIONAL ELEMENTS | PROMEGA CORPORATION (US) | 2016-12-08 | — | — | WO | disclosed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| EP-1846365-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006084369-A9 | DIAMINE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006084369-A9 | DIAMINE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2007-01-11 | — | — | WO | disclosed |
| US-20060235050-A1 | Diamine calcium channel blockers | NUEROMED TECHNOLOGIES, INC. (CA) | 2006-10-19 | — | — | US | disclosed |
| WO-2006084369-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006084369-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235050-A1 | Diamine calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | TDP1 1412/4885MAOA 834/4885MAOB 535/4885 |
| US-12637480-B2 | Heterocyclic compounds as sting modulators | STING1, IFNAR1, IRF3 | TDP1 508/4885MAOA 2205/4885MAOB 1586/4885 |
| US-20250313557-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVE COMPOUNDS AS TLR7/8 MODULATORS | TLR7, TLR8, TLR3 | TDP1 1884/4885MAOA 3859/4885MAOB 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.